JNJ MedTech

JNJ MedTech is the medical-technology business of Johnson & Johnson, a diversified healthcare company headquartered in New Brunswick, New Jersey. The name is used for Johnson & Johnson's portfolio of surgical, orthopaedic, cardiovascular, neurovascular, electrophysiology, vision and other medical-device activities. It is not a separately incorporated public company or an independently listed stock; it operates within the Johnson & Johnson corporate structure and is presented alongside the company's Innovative Medicine business. The portfolio draws on businesses that Johnson & Johnson built or acquired over many decades. Its roots include Ethicon, which became associated with sutures, wound closure and surgical products; DePuy, an early orthopaedic-device company acquired by Johnson & Johnson in 1998; and Synthes, acquired in 2012 and combined with DePuy to create DePuy Synthes. Other major platforms include Biosense Webster in cardiac electrophysiology, Cerenovus in neurovascular care, Mentor in breast aesthetics and reconstruction, and Johnson & Johnson Vision in ophthalmic surgery and vision-care technology. The company also incorporates newer businesses and technologies obtained through acquisitions, partnerships and internal research. JNJ MedTech serves hospitals, surgeons, clinicians and patients rather than operating mainly as a consumer-facing brand. Its products are used in operating rooms, catheterization laboratories, electrophysiology suites, neurointerventional procedures, orthopaedic surgery, ophthalmic surgery and other clinical settings. The business competes through clinical evidence, procedural expertise, physician education, regulatory approvals, hospital relationships and the ability to provide integrated systems rather than isolated devices. Because many products are used in high-risk or highly regulated procedures, product development and commercialization are subject to extensive quality, safety and regulatory requirements. Johnson & Johnson began using the J&J MedTech identity as a clearer umbrella for its medical-device activities during a broader corporate-brand and portfolio transition. In 2023, Johnson & Johnson introduced JNJ MedTech as the name for its MedTech business, while retaining established operating and product brands such as DePuy Synthes, Ethicon, Biosense Webster, Cerenovus and Johnson & Johnson Vision. The naming change followed the planned separation of the consumer-health business, which became Kenvue, and was intended to distinguish the company's medical-technology activities from its pharmaceutical business. The current business spans both established procedural franchises and growth areas. Orthopaedics includes joint reconstruction, trauma, sports medicine and spine-related products. Surgery includes advanced energy, stapling, wound closure, surgical instruments and digital or robotic-enabling technologies. Cardiovascular and specialty areas include electrophysiology, neurovascular intervention and selected structural-heart activities. Vision includes ophthalmic-surgery systems, intraocular lenses and related technologies. The exact portfolio changes over time as Johnson & Johnson launches products, acquires companies, divests activities or reorganizes businesses. JNJ MedTech's corporate identity is therefore best understood as an umbrella business brand rather than a single product line. Its scale, international distribution and broad clinical portfolio make it one of the prominent global medical-device operations, but financial reporting and governance are conducted through Johnson & Johnson rather than through a separately traded JNJ MedTech entity.

JNJ MedTech is the umbrella identity for Johnson & Johnson's medical-device activities. Its history is therefore a composite history of Johnson & Johnson operating companies, product franchises and acquisitions rather than the history of a single standalone corporation founded under that name. Johnson & Johnson entered medical products through businesses associated with surgery and wound care. Ethicon became one of the best-known names in the portfolio through sutures and other wound-closure products, later expanding into surgical instruments, energy devices, stapling and other operating-room technologies. These activities helped establish the company's long-term relationship with surgeons and hospitals and created a base for subsequent expansion into broader procedure-based medicine. Orthopaedics became another major pillar. Johnson & Johnson acquired DePuy in 1998, bringing a recognized orthopaedic-device business into the group. In 2012, Johnson & Johnson completed the acquisition of Synthes. The two businesses were combined as DePuy Synthes, creating a large orthopaedic platform covering areas such as joint reconstruction, trauma, sports medicine and spine. The acquisition materially increased the scale and geographic reach of Johnson & Johnson's device operations. The portfolio subsequently broadened across minimally invasive and specialist procedures. Biosense Webster became a major electrophysiology platform focused on technologies used to diagnose and treat cardiac rhythm disorders. Cerenovus represented Johnson & Johnson's neurovascular activities, including devices used in interventional treatment of conditions affecting blood vessels in the brain. Johnson & Johnson also developed or acquired ophthalmic and vision businesses, including surgical systems and intraocular-lens activities, and maintained Mentor in breast aesthetics and reconstruction. The organization changed its public-facing architecture during Johnson & Johnson's separation of its consumer-health activities. Johnson & Johnson's consumer brands were placed in Kenvue, which became an independently traded company in 2023. After that transition, the continuing Johnson & Johnson group emphasized two major operating businesses: Innovative Medicine and MedTech. The JNJ MedTech identity was introduced to provide a common umbrella for the medical-device portfolio while preserving the specialist names that clinicians already recognized. The business has continued to rely on a combination of internal research, acquisitions, licensing, partnerships and commercialization of technologies developed within its operating companies. Its products generally require regulatory clearance or approval, manufacturing controls, clinical support and post-market monitoring. As a result, the history of JNJ MedTech includes not only product launches and acquisitions but also portfolio decisions, regulatory actions and changes in procedure adoption. Today, JNJ MedTech operates internationally across orthopaedics, surgery, cardiovascular and electrophysiology, neurovascular intervention, vision and related medical technologies. Johnson & Johnson reports the business through its corporate financial and investor-relations structure. JNJ MedTech is consequently a corporate and commercial umbrella brand, not a separate listed issuer with its own ticker, standalone public financial statements or independently verified founding date.

• 2023

  JNJ MedTech identity is introduced

  [3]Johnson & Johnson announces new company brand identityjnj.com

  Johnson & Johnson introduced JNJ MedTech as the umbrella identity for its medical-device business.

• 2023

  Kenvue becomes an independent company

  [4]Johnson & Johnson completes separation of Kenvuejnj.com

  The separation of the consumer-health business into Kenvue helped define the continuing Johnson & Johnson portfolio around Innovative Medicine and MedTech.

• 2017

  Cerenovus brand is introduced

  [6]Cerenovus brand is introducedjnj.com

  Johnson & Johnson brought its neurovascular activities together under the Cerenovus name.

• 2012

  Synthes acquisition expands orthopaedics

  [5]Johnson & Johnson completes acquisition of Synthesjnj.com

  Johnson & Johnson completed the acquisition of Synthes and combined it with DePuy to form DePuy Synthes.

• 1998

  DePuy joins Johnson & Johnson

  [1]Johnson & Johnson company timelinejnj.com

  Johnson & Johnson completed its acquisition of DePuy, expanding its orthopaedic-device activities.

• 1886

  Johnson & Johnson is founded

  [1]Johnson & Johnson company timelinejnj.com

  Johnson & Johnson was established in the United States and later developed the healthcare businesses that ultimately included its medical-device operations.

A global, clinically oriented medical-technology platform serving hospitals and healthcare professionals across surgery, orthopaedics, cardiovascular care, neurovascular intervention and vision. The umbrella emphasizes procedure-based innovation and a portfolio of established specialist businesses.

• Orthopaedics

  DePuy Synthes

  DePuy Synthes is Johnson & Johnson's principal orthopaedic platform. Its portfolio includes products and systems for joint reconstruction, trauma, sports medicine and spine-related procedures. The business supplies implants, instruments and procedural technologies used by orthopaedic surgeons and hospitals.

• Surgery

  Ethicon

  Ethicon is the group's surgical-products franchise. It is associated with sutures and wound closure and also offers surgical stapling, advanced energy, instruments and other technologies used in open, laparoscopic and minimally invasive procedures.

• Cardiac electrophysiology

  Biosense Webster

  Biosense Webster develops technologies for cardiac electrophysiology, including systems and catheter-based tools used to map the heart and support ablation procedures for cardiac arrhythmias. Its products are used by electrophysiologists in specialized cardiac-care settings.

• Neurovascular intervention · 2017

  Cerenovus

  Cerenovus is the neurovascular business of JNJ MedTech. It develops interventional devices used in the treatment of conditions involving blood vessels in the brain, including technologies used in stroke and aneurysm procedures.

• Vision and ophthalmic surgery

  Johnson & Johnson Vision

  Johnson & Johnson Vision includes ophthalmic-surgery and vision-related activities. The portfolio has included intraocular lenses and surgical technologies used in procedures such as cataract surgery, together with other products serving eye-care professionals.

• Aesthetics and reconstruction

  Mentor

  Mentor is associated with breast aesthetics and reconstruction products. Its devices are used in reconstructive and aesthetic procedures and are supplied through the professional healthcare market.

• 2023

  Creation of the JNJ MedTech umbrella identityStrategy

  Background

  Johnson & Johnson was separating its consumer-health activities into Kenvue and needed a clearer identity for the continuing medical-device business.

  Action taken

  The company introduced JNJ MedTech as the umbrella identity for its medical-technology activities while retaining specialist operating brands.

  Aftermath

  The change clarified the distinction between Johnson & Johnson's MedTech and Innovative Medicine businesses without creating a separately listed MedTech company.

  Source

• 2012

  Acquisition of SynthesM&A

  Background

  Johnson & Johnson sought to expand its orthopaedic-device business and strengthen its position across trauma, joint reconstruction and related surgical procedures.

  Action taken

  The company completed the acquisition of Synthes and combined the business with DePuy under the DePuy Synthes platform.

  Aftermath

  The transaction created a larger orthopaedic franchise within Johnson & Johnson's medical-device portfolio.

  Source

1. 1Johnson & Johnson company timelinejnj.com
2. 2Johnson & Johnson MedTechjnjmedtech.com
3. 3Johnson & Johnson announces new company brand identityjnj.com
4. 4Johnson & Johnson completes separation of Kenvuejnj.com
5. 5Johnson & Johnson completes acquisition of Synthesjnj.com
6. 6Cerenovus brand is introducedjnj.com